Business Description
Immuno-Biological Laboratories Co Ltd
ISIN : JP3921300004
Description
Financial Strength
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 3.11 | |||||
Equity-to-Asset | 0.78 | |||||
Debt-to-Equity | 0.19 | |||||
Debt-to-EBITDA | 1.88 | |||||
Interest Coverage | 92.3 | |||||
Piotroski F-Score | 7/9 | |||||
Altman Z-Score | 8.67 | |||||
Beneish M-Score | -2.24 | |||||
WACC vs ROIC |
Growth Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 10.7 | |||||
3-Year Book Growth Rate | -8.1 |
Momentum Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 59.09 | |||||
9-Day RSI | 51.35 | |||||
14-Day RSI | 48.8 | |||||
6-1 Month Momentum % | -12.87 | |||||
12-1 Month Momentum % | -24.19 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 4.9 | |||||
Quick Ratio | 3.65 | |||||
Cash Ratio | 2.85 | |||||
Days Inventory | 393.78 | |||||
Days Sales Outstanding | 89.85 | |||||
Days Payable | 5.67 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Shareholder Yield % | -0.02 |
Profitability Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 63.34 | |||||
Operating Margin % | 12.77 | |||||
Net Margin % | 22.86 | |||||
FCF Margin % | 14.1 | |||||
ROE % | 16.56 | |||||
ROA % | 12.7 | |||||
ROIC % | 19.1 | |||||
3-Year ROIIC % | -121.67 | |||||
ROC (Joel Greenblatt) % | 22.36 | |||||
ROCE % | 10.23 | |||||
Years of Profitability over Past 10-Year | 1 |
GF Value Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 22.91 | |||||
PE Ratio without NRI | 23.6 | |||||
PS Ratio | 5.24 | |||||
PB Ratio | 3.38 | |||||
Price-to-Tangible-Book | 3.38 | |||||
Price-to-Free-Cash-Flow | 37.13 | |||||
Price-to-Operating-Cash-Flow | 31.96 | |||||
EV-to-EBIT | 29.95 | |||||
EV-to-EBITDA | 29.95 | |||||
EV-to-Revenue | 4.62 | |||||
EV-to-FCF | 31.51 | |||||
Price-to-Median-PS-Value | 0.65 | |||||
Price-to-Graham-Number | 1.88 | |||||
Price-to-Net-Current-Asset-Value | 4.7 | |||||
Price-to-Net-Cash | 11.23 | |||||
Earnings Yield (Greenblatt) % | 3.34 | |||||
FCF Yield % | 2.7 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Immuno-Biological Laboratories Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil 円) | 816.701 | ||
EPS (TTM) (円) | 20.036 | ||
Beta | 0.33 | ||
Volatility % | 33.69 | ||
14-Day RSI | 48.8 | ||
14-Day ATR (円) | 23.053927 | ||
20-Day SMA (円) | 466 | ||
12-1 Month Momentum % | -24.19 | ||
52-Week Range (円) | 358 - 679 | ||
Shares Outstanding (Mil) | 9.31 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 7 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Immuno-Biological Laboratories Co Ltd Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Immuno-Biological Laboratories Co Ltd Stock Events
Event | Date | Price(円) | ||
---|---|---|---|---|
No Event Data |
Immuno-Biological Laboratories Co Ltd Frequently Asked Questions
What is Immuno-Biological Laboratories Co Ltd(TSE:4570)'s stock price today?
When is next earnings date of Immuno-Biological Laboratories Co Ltd(TSE:4570)?
Does Immuno-Biological Laboratories Co Ltd(TSE:4570) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |